CORRECTION article
Front. Pharmacol.
Sec. Respiratory Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1667879
This article is part of the Research TopicAcute and Chronic Lung Injury: Therapeutic Targets and DrugsView all 11 articles
Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury
Provisionally accepted
- Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
* Correspondence: Zhihua Chen (zhihuachen@zju.edu.cn), Huaqiong Huang (zr_hhq@zju.edu.cn) Correction on: Liu Z, Fang D, Chen K, Dong L, Huang H and Chen Z (2025) Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury. Front. Pharmacol. 16:1590458. doi: 10.3389/fphar.2025.1590458 In the published article, there was an error. [In the published article, there was an error in the description of the regulatory status of TJ0113. The article incorrectly stated that TJ0113 had received clinical approval for Alport syndrome from both the China National Medical Products Administration and the U.S. Food and Drug Administration. In fact, TJ0113 has only been approved to initiate a Phase I clinical trial in China (CTR20232426) for the treatment of Alport syndrome, and has not received clinical approval for this indication from the U.S. The corrected sentence appears below: "Notably, TJ0113 has been approved to initiate clinical trial for Alport syndrome, Parkinson's disease and depression in China (CTR20232426, CTR20243324, CTR20252210).]"
Keywords: Acute Lung Injury, Mitophagy inducer, TJ0113, NF-κB, NLRP3 inflammasome
Received: 17 Jul 2025; Accepted: 25 Jul 2025.
Copyright: © 2025 Liu, Fang, Chen, Dong, Huang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Huaqiong Huang, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Zhihua Chen, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.